OXFORD, England, Oct. 19 /PRNewswire/ -- Orchid BioSciences, Inc. (Nasdaq: ORCH - news) today announced the establishment of Orchid BioSciences Europe Ltd., its wholly owned European subsidiary located in Oxford, U.K. This new subsidiary, headed by vice president and managing director Christopher P. Ashton, Ph.D., will focus on developing business opportunities in Europe for Orchid's single nucleotide polymorphism (SNP) scoring and genetic diversity analysis products and services.
``This is an exciting time for Orchid, as we formally launch our facility to serve the fast-growing European market,'' said Dale Pfost, Ph.D., chairman, president and chief executive officer of Orchid. ``Orchid is committed to being a worldwide leader in genetic diversity products and services, and having a major presence in the European marketplace is an integral part of our strategy.''
Orchid's Oxford facility currently houses marketing, sales and business development functions. Orchid intends to add SNP scoring and clinical DNA testing service capabilities in the U.K. facility in the next 12 to 18 months.
``We believe that Europe offers a strong growth opportunity for Orchid, so it is particularly appropriate that we have now begun to establish a significant presence here,'' said Dr. Ashton. ``As post-genomics research accelerates, Orchid's leading genotyping technologies will help our European customers to incorporate pharmacogenetics into their drug discovery, development and marketing efforts.''
* Contact Information:
* Orchid BioSciences Europe, Ltd.
* John Eccles House
* Robert Robinson Avenue
* Oxford Science Park
* Oxford, OX4 4GP
* United Kingdom
* Telephone: +44 (0) 1865 338022
* Fax: +44 (0) 1865 338121
* E-mail: cashton@orchid.com |
